Valbiotis : Commercialisation de « Valbiotis®PRO Cholestérol » en France prévue pour le mois de mai
>Totum-070 arrive sur le marché français en mai 2024… comme prévu - Conformément à ses objectifs préalablement annoncés, la société mettra sur le marché français son premier complément alimentaire « Valbiotis®PRO Cholestérol » composé exclusivement de Lipidrive® (ex-TOTUM 070), pour la prise en charge de l’hypercholestérolémie légère à modérée en mai 2024. Le médicament sera promu à travers des attachés à la promotion médicale (APM) internes et sera disponible en phar...Valbiotis SA Formerly known as Valbiotis SAS. Valbiotis SA is a France-based company engaged in the biotechnology industry. The Company specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. It seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The Company prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. It provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.